Welcome to our dedicated page for Therapeuticsmd SEC filings (Ticker: TXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TherapeuticsMD, Inc. (TXMD) SEC filings page brings together the company’s official regulatory documents, which describe its status as a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TXMD. Filings such as Form 8-K, the definitive proxy statement on Schedule 14A, and other periodic reports provide detailed information on the company’s financial condition, governance, and capital structure.
Recent Form 8-K filings furnished by TherapeuticsMD include disclosures of quarterly financial results, where the company reports net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses. These filings often incorporate press releases that explain how the company’s transition to a pharmaceutical royalty business and its focus on cost control affect its reported results.
The company’s definitive proxy statement outlines matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, the ratification of the independent auditor, and proposals to amend the company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock. Voting results for these proposals are reported in subsequent Form 8-K filings, which detail how stockholders voted on director elections, say-on-pay, say-on-frequency, auditor ratification, and share authorization changes.
On Stock Titan, TXMD filings are updated as they are made available through the SEC’s EDGAR system. Each filing can be reviewed in full, and AI-powered tools can help summarize key points, such as the outcomes of stockholder meetings, changes to authorized share capital, and the company’s reported financial performance. This allows users to quickly understand the main elements of TherapeuticsMD’s regulatory disclosures while retaining access to the complete original documents for deeper analysis.
TherapeuticsMD has transformed into a pharmaceutical royalty company after the December 30, 2022 Mayne Transaction that generated $140.0 million in cash plus approximately $12.1 million for net working capital and $1.0 million in prepaid royalties. Under the Mayne License Agreement Mayne Pharma pays royalties of 8.0% on the first $80.0 million of U.S. annual net sales and 7.5% thereafter, with a $3.0 million minimum annual royalty for 12 years (adjusted 3% annually) and a 20-year royalty term.
For the quarter ended June 30, 2025 TherapeuticsMD reported $952 thousand of license revenue (up from $234 thousand a year earlier) and net income of $551 thousand or $0.05 per share. Cash totaled $6.069 million and royalty receivables were $3.743 million (short-term) and $14.840 million (long-term). The company discloses concentration (100% of license revenue from Mayne, Theramex and Knight), ongoing disputes with Mayne Pharma over net working capital and indemnification that gave rise to litigation, and states substantial doubt about its ability to continue as a going concern for the next twelve months.
TherapeuticsMD, Inc. disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02 via Item 7.01. The filing makes clear the material in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and includes an explicit disclaimer that the company has no obligation to publicly update any forward-looking statements. The report lists the press release and an Inline XBRL cover page as exhibits.